Premium
Use of the platelet function analyser (PFA‐100 ® ) to quantify the effect of low dose aspirin in patients with ischaemic heart disease
Author(s) -
Coakley M.,
Self R.,
Marchant W.,
Mackie I.,
Mallett S. V.,
Mythen M.
Publication year - 2005
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/j.1365-2044.2005.04291.x
Subject(s) - aspirin , medicine , platelet , ischaemic heart disease , anesthesia
Summary Continuing aspirin up until surgery in cardiac surgical patients may increase peri‐operative blood loss. It is possible that there is a subset of patients particularly sensitive to aspirin. The platelet function analyser (PFA‐100 ® ) can demonstrate the antiplatelet effect of aspirin. This study was designed to assess the effect of daily 75 mg aspirin on platelet function, as measured by the PFA‐100 ® , in 92 patients with ischaemic heart disease. Patients were classified into three groups according to their PFA‐100 ® results; aspirin hyper‐responders (16%), aspirin normal responders (33%) and aspirin non‐responders (51%). The PFA‐100 ® has potential as a screening tool to identify patients who are either hyper‐responsive or resistant to aspirin. Pre‐operative PFA‐100 ® screening to isolate aspirin hyper‐responders could enable the vast majority of patients to continue with aspirin therapy pre‐operatively, avoiding the risks of stopping treatment.